now the technologists of a company of scientists in the research institute royan was able to produce kimiacel drug by successfully producing the first phase of the trial. the donor must be examined in terms of all tests and those international rules. when it is confirmed, we have the stage of aspiration, or the separation of brain and bone from the person. then he enters the clean room. sample and clones are separated there and the best clone is selected and then that best clone is cultivated in gmp conditions and mass taxed and according to the theft that has taken place for which diseases how much cells should be used put us in the mold we actually manufacture these products. the first stage of testing this drug is on two groups of patients. it has been concluded with positive results that this product was transplanted in six patients for rheumatoid arthritis and also in five patients for back pain patients due to disc destruction and after the duration of the treatment for these dear patients , we realized that this product is completely harmless. there is a risk , it can be done and it ca